The 2019 National University of Singapore (NUS) Initiative to Improve Health in Asia Leadership Development Programme (NIHA LDP) was held at NUS, Singapore from the 24th – 29th June. The event aimed to equip policy-makers with an understanding of  health technology assessment (HTA) for health care p

Welcome to Bhutan, the land of the Thunder Dragon nested amidst the breathtaking grandeur of the Eastern Himalayas. Guided by the concept of the Gross National Happiness, Bhutan’s constitution mandates access to free basic public health services, for both modern and traditional medicine. Nonetheless

Aiming at appropriate preparation for the future development of individualized and regenerative medicine (in particular, gene, stem cell and tissue engineering therapies), the Health Intervention and Technology Assessment (HITAP) program has agreed to conduct a study to provide an insight on elements necessary for national policymaking in Thailand.

Advanced health biotechnologies in Thailand: redefining policy directions. Román Pérez Velasco1*, Usa Chaikledkaew2,3, Chaw Yin Myint2 , Roongnapa Khampang2 , Sripen Tantivess2 and Yot Teerawattananon2* Abstract Background: Thailand faces a significant burden in terms of treating and managi

For full text, click here http://www.translational-medicine.com/content/pdf/1479-5876-11-1.pdf

โครงการประเมิน เทคโนโลยีและนโยบายด้านสุขภาพ กระทรวงสาธารณสุข ได้ทบทวน เอกสารทางวิชาการ รวมทั้งรายงานและบทความการศึกษาวิจ

Antimicrobial Resistance (AMR) occurs when pathogens (bacteria, viruses, fungi, and parasites) develop a resistance or tolerance to the medicines that are used to combat these microorganisms, such that these treatments are no longer effective. AMR has been increasing in low-, middle- and high-income

The development of medical innovation is a key strategic priority of Thailand under the 13th National Economic and Social Development Plan, which aims to position the country as a hub for high-value medical and healthcare services. However, despite the continuous growth of medical research in Thailand, many innovations have not successfully progres

The company said the drug sovaprevir, when given along with the standard therapy of pegylated interferon and ribavirin, showed no detectable virus level in a majority of patients four weeks after the end of the treatment period.Of the 39 patients who received 12 weeks of additional standard therapy

Katharina Kieslich1,*, Jesse B. Bump2 , Ole Frithjof Norheim3 , Sripen Tantivess4 and Peter Littlejohns1 1 Faculty of Life Sciences & Medicine, Division of Health and Social Care Research, King’s College London, London, UK 2 Department of Global Health and Population, Harvard T. H. Chan School o